



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.

TEL : 0260-2430027
Email : hrm@gtbl.in.net

CIN No. L24230GJ1981PLC004878

GTBL: CS: BSE-CORR/2023-24

10th August, 2023

BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 506879

Dear Sir/Madam,

Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Meeting Commencement Time : 10:30 A.M.
Meeting Conclusion Time : 10:50 A.M.

The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter ended 30th June, 2023.

A copy of Unaudited Financial Results of the Company for the Quarter ended 30th June, 2023 together with Limited Review Report is enclosed herewith.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record.

Thanking you,

Yours Faithfully,

For **GUJARAT THEMIS BIOSYN LIMITED**

Rahul Soni
Company Secretary & Compliance Officer



Independent Auditor's Review report on quarterly unaudited financial results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review report to
The Board of Directors
GUJARAT THEMIS BIOSYN LIMITED


We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended June 30, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co
Chartered Accountants
FRN: 103429W



CA Amit Maheshwari
Partner

M. No.: 428706

UDIN: 234287 06BHAY FK5424

Place : Mumbai

Date : August 10, 2023



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter ended June 30, 2023

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended		Year Ended	
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
I	Income from operations	4,958.80	2,817.27	4,494.44	14,897.29
II	Other Income	107.47	139.86	142.25	602.38
III	Total Income (I+II)	5,066.27	2,957.12	4,636.69	15,499.67
IV	Expenditure				
	(a) Cost of raw material consumed	641.33	695.67	767.19	2,973.03
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock in Trade	708.39	(497.91)	318.33	(323.54)
	(d) Employee benefits expense	207.75	214.54	174.71	774.71
	(e) Finance Cost	2.50	2.49	6.24	20.07
	(f) Depreciation and Amortisation expenses	74.90	76.92	56.98	257.57
	(g) Other Expenses				
	i) Stores and spares	93.53	75.57	113.88	428.61
	ii) Power	502.87	453.11	430.12	1,788.27
	iii) Fuel	145.45	170.58	205.92	748.23
	iv) Water	33.15	26.69	27.38	104.05
	v) Other expenditure	275.68	186.36	179.05	982.17
	Total Expenses	2,685.55	1,404.02	2,279.78	7,753.19
V	Profit/(Loss) before Exceptional Items and Tax (III-IV)	2,380.72	1,553.11	2,356.91	7,746.48
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before Tax (V-VI)	2,380.72	1,553.11	2,356.91	7,746.48
VIII	Tax expenses				
	(a) Current Tax	598.98	383.35	599.12	1924.06
	(b) Deferred Tax	9.58	0.54	(19.25)	25.54
IX	Net Profit/(Loss) after tax (VII-VIII)	1,772.16	1,169.22	1,777.04	5,796.88
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss				
	(i) remeasurement of defined benefit plans;	2.02	16.18	(2.70)	8.09
	(ii) Income Tax relating to items that will not be reclassified	(0.53)	(4.20)	0.70	(2.10)
	(b) Items that will be reclassified to Profit or Loss				
	(i) Income Tax relating to items that will be reclassified to	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	1,773.65	1,181.19	1,775.04	5,802.87
XII	Paid-up equity share capital	726.44	726.44	726.44	726.44
XIII	Other Equity	-	-	-	14,188.15
XIV	Earnings Per Share (Basic and Diluted)	12.20	8.05	12.23	39.90



Notes:

- 1 The financial results for the quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 10, 2023.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The figures of the last quarter ended March 31, 2023 of the previous financial year is balancing figures between audited figures of the full financial year and published year-to-date figures for the nine months ended.
- 5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai
Date : 10-08-2023

For GUJARAT THEMIS BIOSYN LIMITED

Dr. DINESH PATEL
Chairman
DIN : 00033273

